|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Sage Therapeutics, Inc. (SAGE) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
58,290,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Sage Therapeutics is a biopharmaceutical company focused on developing and commercializing medicines with the potential to transform the lives of people with debilitating disorders of the brain. Co.'s principal product, ZULRESSO, is a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. Co.'s other product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder, and PPD. Co. has a portfolio of other compounds that target GABAA receptors, including SAGE-324. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
3,000 |
25,500 |
| Total Buy Value |
$0 |
$0 |
$87,779 |
$839,364 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
2 |
4 |
| Total Shares Sold |
0 |
0 |
0 |
11,643 |
| Total Sell Value |
$0 |
$0 |
$0 |
$519,413 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Robichaud Albert |
Chief Scientific Officer |
• – – |
2021-06-15 |
4 |
D |
$58.80 |
$67,267 |
D/D |
(1,144) |
139,651 |
|
- |
|
| Robichaud Albert |
Chief Scientific Officer |
• – – |
2021-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
140,795 |
|
- |
|
| Iguchi Kimi |
CFO & Treasurer |
• – – |
2021-04-13 |
4 |
OE |
$1.36 |
$2,040 |
D/D |
1,500 |
36,855 |
|
- |
|
| Jonas Jeffrey M |
Chief Innovation Officer |
• • – |
2021-01-27 |
4 |
OE |
$0.45 |
$810 |
D/D |
1,800 |
56,330 |
|
- |
|
| Iguchi Kimi |
CFO & Treasurer |
• – – |
2021-01-05 |
4 |
OE |
$1.36 |
$2,380 |
D/D |
1,750 |
35,355 |
|
- |
|
| Biogen Ma Inc. |
10% Owner |
– – • |
2020-12-31 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
6,241,473 |
|
- |
|
| Iguchi Kimi |
CFO & Treasurer |
• – – |
2020-04-30 |
4 |
OE |
$1.36 |
$5,440 |
D/D |
4,000 |
33,261 |
|
- |
|
| Iguchi Kimi |
CFO & Treasurer |
• – – |
2019-12-10 |
4 |
OE |
$1.36 |
$680 |
D/D |
500 |
29,261 |
|
- |
|
| Iguchi Kimi |
CFO & Treasurer |
• – – |
2019-12-09 |
4 |
OE |
$1.36 |
$20,400 |
D/D |
15,000 |
28,761 |
|
- |
|
| Jonas Jeffrey M |
President & CEO |
• • – |
2019-12-09 |
4 |
B |
$64.20 |
$481,500 |
D/D |
7,500 |
54,530 |
0.01 |
- |
|
| Robichaud Albert |
Chief Scientific Officer |
• – – |
2019-12-09 |
4 |
B |
$64.16 |
$1,604,000 |
D/D |
25,000 |
136,400 |
0.01 |
- |
|
| Robichaud Albert |
Chief Scientific Officer |
• – – |
2019-12-09 |
4 |
OE |
$1.36 |
$316,746 |
D/D |
15,743 |
111,400 |
|
- |
|
37 Records found
|
|
Page 2 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
